DailyIQ
Last updated 3 minutes ago

MTD·Mettler-Toledo International Inc.

$.
+. (+.%)
After Hours
High
$1,303.45
Open
$1,295.92
Market Cap
26.03B
52W High
$1,525.17
Low
$1,279.36
P. Close
$1,296.21
P/E
29.75
52W Low
$1,023.05
Fwd P/E
25.28
DailyIQ Est.
$1333.13
Technical Score (1D)
64
BUY
News Sentiment
50
MIXED
Mettler‑Toledo International was recently dropped from the Russell 1000 Dynamic Index, a move that signals softer organic revenue growth and heightened scrutiny of the company’s earnings resilience. Management has highlighted ongoing margin pressures and tariff‑related costs that could erode near‑term earnings, suggesting that the firm may need to tighten cost controls to maintain profitability. The index change does not alter the primary catalyst for the stock, but it does raise the stakes for how quickly MTD can demonstrate margin stability in the coming weeks. Analysts have recently revised their price targets upward, with Argus Research lifting MTD’s target to $1,425 and Evercore ISI raising it to $1,350, reflecting confidence in the company’s strategic initiatives and potential margin expansion. However, a Barclays downgrade of the target to $1,300, citing concerns over cost pressures, introduces uncertainty about the near‑term valuation ceiling. The company’s Q2 2024 earnings are expected to show modest single‑digit growth, with analysts focusing on revenue, operating margin, and guidance for the full year, which will be critical for confirming the company’s ability to sustain profitability amid commodity price volatility. In the longer term, MTD’s valuation appears to be at a premium relative to peers, with a discounted cash‑flow model suggesting intrinsic value near the current price but market multiples indicating potential overpricing, a scenario that could dampen upside if earnings fail to accelerate. Traders should also monitor options activity, as a recent spike in open interest and implied volatility suggests market participants are positioning for potential volatility around the upcoming earnings event. Finally, the firm’s exposure to the life sciences and industrial sectors means that any shifts in demand for precision measurement instruments, or changes in tariff policy, could materially affect the company’s revenue trajectory over the next few weeks.
Earnings Summary
Mettler‑Toledo International Inc. (MTD) supplies precision instruments and related services to laboratory and industrial customers worldwide, operating primarily in the diagnostics and research sector of healthcare. The company’s dual‑segment model—laboratory instruments and industrial instruments—serves life science, food production, and chemical industries, positioning it within a niche yet essential market for analytical and weighing solutions. In the most recent two quarters, MTD’s revenue fell from $1,129.74 million in Q4 2025 to $947.13 million in Q1 2026, a 16.8% decline, while EPS dropped from $13.36 to $8.91, a 33.5% decrease; this contrasts with the prior two quarters where revenue rose from $983.22 million in Q2 2025 to $1,029.70 million in Q3 2025 and EPS climbed from $10.09 to $11.15. Despite the recent downturn, MTD consistently beat earnings estimates in all six quarters reported, with Q4 2025 revenue surpassing the $1,115.61 million estimate and Q1 2026 revenue narrowly missing the $951.22 million forecast. Historically, the company has maintained positive YoY growth, with revenue up 8.2% in Q4 2025 versus Q4 2024 and 7.2% in Q1 2026 versus Q1 2025, and EPS rising 7.7% and 8.8% respectively, underscoring a resilient earnings trajectory even amid market volatility. Recent news highlights an upcoming Q2 2026 earnings release that will shed light on revenue, margins, and potential new product launches; analysts have raised price targets to $1,350–$1,425 amid confidence in cost‑control initiatives, yet concerns remain over a 2.7% YoY organic revenue growth lagging peers, prompting scrutiny of demand recovery in life sciences and commodity‑price exposure. Investors should watch the forthcoming earnings call for guidance on full‑year revenue growth, margin expansion, and any updates on supply‑chain constraints or regulatory changes, as these factors will shape the company’s valuation trajectory in the next 10–15 trading days.

EPS

EstBeatMiss
$7.06$8.84$10.62$12.40$14.18Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$10.80 - -
Q1'26$8.79$8.91+1.4%
Q4'25$12.93$13.36+3.3%
Q3'25$10.66$11.15+4.6%
Q2'25$9.60$10.09+5.1%
Q1'25$7.88$8.19+3.9%

Revenue

EstBeatMiss
$847M$927M$1.0B$1.1B$1.2BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.0B - -
Q1'26$951M$947M-0.4%
Q4'25$1.1B$1.1B+1.3%
Q3'25 - $1.0B -
Q2'25 - $983M -
Q1'25 - $884M -

Market Data

MTD Stock Snapshot

MTD is currently trading at $1296.17, giving Mettler-Toledo International Inc. a market cap of 26.03B and a P/E ratio of 29.8. Today's range spans $1279.36–$1303.45, with shares opening at $1295.92 and moving down $0.04 (0.0%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 50/100.

Over the past year MTD has traded between $1023.05 and $1525.17 - the current price is +26.7% off the 52-week low and -15.0% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $1315.33 (range $1194.00–$1550.00), implying upside of +1.5%.

It's a pause for MTD: technical score 64/100 (HOLD), sentiment neutral (50/100), price $1296.17 (in the middle of its 52-week range). (P/E: 29.8) At 26.03B in Healthcare market cap, pauses like this often occur when the stock has run ahead of near-term fundamental catalysts and is waiting for earnings or macro data to validate the prior move. Annual range: $1023.05–$1525.17. The consolidation is the story for now.

In neutral phases, large-cap Healthcare names like MTD are often where sector rotation debates play out quietly — at 26.03B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 64/100 (HOLD) and neutral sentiment (50/100) at $1296.17 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.